The current global healthcare response to the COVID-19 pandemic is focused on a widespread vaccination campaign, which started with the authorization of Pfizer/BioNTech and Moderna mRNA COVID-19 vaccines in December 2020. Local injection site reactions have been described during the clinical trials of both the abovementioned mRNA vaccines; skin rashes were additionally reported in the trial of Moderna. Despite this, cutaneous adverse reactions to the vaccines and their timing remain to date poorly characterized.
Lymphomatoid drug reaction developed after BNT162b2 (Comirnaty) COVID-19 vaccine manifesting as pityriasis lichenoides et varioliformis acuta-like eruption / Sernicola, A.; Dybala, A.; Gomes, V.; Maddalena, P.; Adotti, F.; Soda, G.; Muharremi, R.; Fino, P.; Del Duca, E.; Grieco, T.. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 0926-9959. - (2022). [10.1111/jdv.17807]
Lymphomatoid drug reaction developed after BNT162b2 (Comirnaty) COVID-19 vaccine manifesting as pityriasis lichenoides et varioliformis acuta-like eruption
Sernicola A.Primo
;Dybala A.Secondo
;Gomes V.;Maddalena P.;Adotti F.;Soda G.;Muharremi R.;Fino P.;Del Duca E.Penultimo
;Grieco T.
Ultimo
2022
Abstract
The current global healthcare response to the COVID-19 pandemic is focused on a widespread vaccination campaign, which started with the authorization of Pfizer/BioNTech and Moderna mRNA COVID-19 vaccines in December 2020. Local injection site reactions have been described during the clinical trials of both the abovementioned mRNA vaccines; skin rashes were additionally reported in the trial of Moderna. Despite this, cutaneous adverse reactions to the vaccines and their timing remain to date poorly characterized.| File | Dimensione | Formato | |
|---|---|---|---|
|
Sernicola_Lymphomatoid drug reaction_2021.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
441.42 kB
Formato
Adobe PDF
|
441.42 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
